Company intelligence / Profile preview

Signos

Burlingame, California, United Statessignos.com ↗

Ownership: Private
Employees: ~115
Development stage: Other

Overview

Signos offers a commercial platform that combines continuous glucose monitoring (CGM) with an AI-powered app to deliver real-time, personalized recommendations for diet and exercise. The system is designed to help users manage weight and improve metabolic health by translating individual glucose responses into actionable insights. Clinical results are not published in the traditional sense, as this is a consumer wellness product rather than a regulated therapeutic intervention[1][3].

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: DeviceDigital therapeutic (AI-driven app)
Industry: Physiological Monitoring

Partnerships

Dexcom Ventures (strategic investor; Dexcom manufactures CGMs used by the platform)Samsung NEXT (investor/partner)Google Ventures/GV (investor/partner)

Beyond the preview

Go deeper on Signos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Signos.

Explore the full profile